Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466647 | 1.00 | TAAR1 (0.38) | TAAR1GABRA1GABRB2IDO1TSHR | |
| SCHEMBL6525315 | 0.84 | APOBEC3G (0.35) | TAAR1GABRA1GABRB2IDO1TSHR | |
| SCHEMBL1293367 | 0.84 | GABRA1 (0.48) | TAAR1GABRA1GABRB2IDO1TSHR | |
| SCHEMBL12787109 | 0.84 | GABRA1 (0.54) | TAAR1GABRA1GABRB2IDO1TSHR | |
| SCHEMBL7925692 | 0.84 | TAAR1 (0.34) | TAAR1GABRA1GABRB2IDO1TSHR | |
| SCHEMBL338177 | 0.84 | GABRA1 (0.38) | GABRA1GABRB2TSHRTRPA1ALDH1A1 | |
| SCHEMBL173876 | 0.84 | ALDH1A1 (0.36) | TAAR1GABRA1GABRB2IDO1TSHR | |
| SCHEMBL8217001 | 0.79 | GABRA1 (0.34) | TAAR1GABRA1GABRB2IDO1TSHR | |
| SCHEMBL29562705 | 0.77 | GABRA1 (0.44) | TAAR1GABRA1GABRB2IDO1TSHR | |
| SCHEMBL305224 | 0.77 | GABRA1 (0.44) | TAAR1GABRA1GABRB2IDO1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729516-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-12479807-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-14 | — | — | US | disclosed |
| EP-3259250-B1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | OXFORD DRUG DESIGN LTD (GB) | 2025-07-02 | — | — | EP | disclosed |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-03-13 | — | — | US | disclosed |
| WO-2024260319-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏恩华药业股份有限公司 | 2024-12-26 | — | — | WO | disclosed |
| EP-4446312-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-10-16 | — | — | EP | disclosed |
| US-20240246950-A1 | Anilino-Pyrazole Derivatives, Compositions and Methods Thereof | Ensem Therapeutics (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
| US-7067653-B2 | Porphyrin Based neuton capture agents for cancer therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040116385-A1 | Treating and preventing viral infections with porphyrin-based compounds | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2004-06-17 | — | — | US | disclosed |
| US-20040106592-A1 | Chelation of charged and uncharged molecules with porphyrin-based compounds | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2004-06-03 | — | — | US | disclosed |
| US-20040014737-A1 | Porphyron based neuton capture agents for cancer therapy | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2004-01-22 | — | — | US | disclosed |
| WO-2001085736-A1 | PORPHYRIN-BASED NEUTRON CAPTURE AGENTS FOR CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-11-15 | — | — | WO | disclosed |
| US-5728712-A | 3,4-disubstituted-phenylsulphonamides and their therapeutic use | CHIROSCIENCE LIMITED (GB) | 1998-03-17 | — | — | US | disclosed |
| WO-1996036611-A1 | 3,4-DISUBSTITUTED-PHENYLSULPHONAMIDES AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-21 | — | — | WO | disclosed |
| US-5026856-A | Bactericides | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1991-06-25 | — | — | US | disclosed |
| EP-0343560-A2 | Isoindoline derivative | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | CYP2B6, CYP2D6, CYP1A2 | TAAR1 492/4885GABRA1 598/4885GABRB2 1307/4885 |
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | KEAP1, NFE2L2, BACH1 | TAAR1 872/4885GABRA1 2492/4885GABRB2 2973/4885 |
| US-20040106592-A1 | Chelation of charged and uncharged molecules with porphyrin-based compounds | HMBS, PPOX, SLC7A1 | TAAR1 3950/4885GABRA1 2535/4885GABRB2 1730/4885 |
| US-12479807-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | TAAR1 4653/4885GABRA1 4017/4885GABRB2 4110/4885 |
| US-20040014737-A1 | Porphyron based neuton capture agents for cancer therapy | PPOX, HMBS, PYGB | TAAR1 4756/4885GABRA1 2202/4885GABRB2 1662/4885 |
| US-20240246950-A1 | Anilino-Pyrazole Derivatives, Compositions and Methods Thereof | CDK2, CDK3, CDK4 | TAAR1 4715/4885GABRA1 4707/4885GABRB2 4551/4885 |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | KEAP1, NFE2L2, BACH1 | TAAR1 872/4885GABRA1 2492/4885GABRB2 2973/4885 |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | KEAP1, NFE2L2, BACH1 | TAAR1 887/4885GABRA1 2506/4885GABRB2 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.